Sirt1在膿毒血癥繼發(fā)的急性肺和腎損傷中的保護(hù)作用
[Abstract]:Sepsis is a potentially fatal systemic inflammatory response, also known as systemic inflammatory response syndrome (SIRS), a refractory disease with high morbidity and mortality from severe infections. Sepsis can also be considered an excess from infection to multiple organ dysfunction syndrome. Sepsis can cause organ dysfunction of failure type. Clinical observation shows that patients with sepsis have a high risk of developing acute lung injury (ALI) and acute kidney injury (AKI). Acute Respiratory Distress Syndrome (ARDS), a severe form of ARDS, often leads to multiple organ failure (MOF) with a clinical mortality rate of about 30% - 50%. In addition, as a natural blood filtration system, the kidney becomes a direct target for organ damage in systemic inflammatory reactors. The expression of Sirt1 was decreased in the elderly. It was also reported that the expression of Sirt1 was decreased in patients with chronic obstructive pulmonary disease (COPD), so we speculated that Sirt1 might play a role in the regulation of inflammation. We used cecum ligation puncture (CLP) and lipopolysaccharide (LPS) to induce sepsis, respectively. To study the effect and mechanism of Sirt1 on lung and kidney injury.
Sirtuin 1 (Sirt1), a member of the Sirtuin family, is a deacetylase first discovered in yeast. Unlike the classical histone deacetylation pathway, Sirt1 exerts its deacetylation function by deacetylating lysine residues to regulate other protein functions, such as nuclear transcription factors kB and p53. Sirt1 has been found to play an important role in inflammation, apoptosis, anti-stress, metabolism, differentiation and aging, while the role of Sirt1 in sepsis has not been well understood. In this study, we used Sirt1 knockout mice to study its role in acute lung and kidney injury induced by sepsis and to further clarify its regulation. Our experiments showed that Sirt1 knockout mice were more susceptible to ALI and AKI induced by sepsis.
In the first part of the experiment, we mainly studied the effect and mechanism of Sirt1 on ALI secondary to sepsis. In the experiment, we performed CLP on the wild type mice with Sirt1 gene knockout and its homology, and successfully induced sepsis model in mice. To understand the infiltration of neutrophils, we examined the activity of myeloperoxidase (MPO) in lung tissue homogenate 24 hours after CLP. Then we used kits to detect IL-6 in serum and lung tissue 6 hours and 24 hours after CLP. In order to further understand the mechanism of Sirt1 regulating pulmonary inflammation, we used Western blot to detect the expression of Sirt1-regulated direct and indirect target proteins in the lung. Our study demonstrated that the activation of NF-kB in the lungs of Sirt1 knockout mice was enhanced, and the downstream adhesion molecule-intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were fine. The expression of extracellular regulated kinase 1/2 (ERK1/2), signal transduction activator 3 (stat3), caspase 3, and caspase 7 were significantly increased. The above results demonstrated that Sirt1 knockout enhanced lung injury by triggering excessive inflammation and related inflammatory complex pathways.
In the second part of the experiment, we mainly studied the role and mechanism of Sirt1 in regulating renal injury secondary to sepsis. We established sepsis model in LPS-induced mice. First, the detection of BUN and KIM-1 in serum showed that renal function was significantly impaired in sepsis. Histological examination revealed that sepsis also caused renal tubular injury and inflammation. Increased inflammation and the production of pro-inflammatory mediators were closely related to the up-regulation of adhesion molecules (such as ICAM-1 and VCAM-1). These early inflammatory reactions caused infiltration of inflammatory cells during renal injury, whereas excessive infiltration of inflammatory cells could be induced. NF-kB regulates the transcription of various inflammatory factors during the regulation of inflammatory factors, thereby affecting the process of inflammation. Sirt1 knockout leads to the activation of NF-kB, and subsequently activated NF-kB leads to the increase of cytokines including IL-6 and TNF-alpha, which is the result of AKI. Significant markers. Cytokines can also activate signaling pathways, such as the cascade of Stat3 and ERK1/2. These experiments have shown that Sirt1 has a protective effect on AKI induced by sepsis and produces its protective mechanism by regulating the activation of NF-kB.
To sum up, Sirt1 plays a protective role in acute lung and kidney injury induced by sepsis. Sirt1 exerts its protective function mainly by regulating the activation of nuclear transcription factors, which in turn leads to the activation of inflammatory pathways such as Stat3, ERK1/2 and caspase. Therapeutic targets for injury.
【學(xué)位授予單位】:吉林大學(xué)
【學(xué)位級(jí)別】:博士
【學(xué)位授予年份】:2014
【分類號(hào)】:R459.7
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 張惠珍,朱玲t(yī) ;慢性肉芽腫1例報(bào)告[J];臨床兒科雜志;1991年04期
2 杜雋銘;一氧化氮延遲吸入法保護(hù)革蘭陰性膿毒血癥豬肺泡毛細(xì)血管膜完整性[J];國(guó)外醫(yī)學(xué).骨科學(xué)分冊(cè);1997年04期
3 鄧烈華,姚華國(guó),邵義明;血必凈對(duì)膿毒血癥患者前降鈣素影響的臨床觀察[J];實(shí)用醫(yī)技雜志;2005年12期
4 林玲,蔡秀軍;膿毒血癥患者外周血白細(xì)胞凋亡與病情及預(yù)后關(guān)系[J];中國(guó)急救醫(yī)學(xué);2005年11期
5 朱志云;李凌;葉紀(jì)錄;;早期中心靜脈血氧飽和度監(jiān)測(cè)在嚴(yán)重膿毒血癥與感染性休克中的意義[J];現(xiàn)代醫(yī)藥衛(wèi)生;2008年20期
6 盛虹;曹偉新;;魚油在膿毒血癥中的應(yīng)用[J];上海交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年01期
7 金杰波;周軍;陳雙;;甲亢治療后繼發(fā)膿毒血癥合并腸外瘺1例報(bào)道[J];嶺南現(xiàn)代臨床外科;2010年02期
8 趙湛元;肖倩霞;張志剛;;血乳酸動(dòng)態(tài)監(jiān)測(cè)對(duì)膿毒血癥預(yù)后的臨床意義[J];臨床醫(yī)藥實(shí)踐;2010年14期
9 宋紅梅;張?zhí)?biāo);;血必凈注射液治療膿毒血癥臨床觀察[J];中國(guó)中醫(yī)急癥;2010年08期
10 閔安如;王偉明;龍連圣;;重型顱腦傷并發(fā)腸源性膿毒血癥的臨床分析[J];南京部隊(duì)醫(yī)藥;2000年05期
相關(guān)會(huì)議論文 前10條
1 王春亭;孟玫;蔣進(jìn)皎;張繼承;任宏生;楚玉峰;曾娟;孟沖;郄國(guó)強(qiáng);于結(jié)濱;;連續(xù)性高容量血液濾過(guò)對(duì)膿毒血癥可溶性黏附分子的影響[A];第三屆重癥醫(yī)學(xué)大會(huì)論文匯編[C];2009年
2 崔微艷;陸潔;鄒靜蓉;何玉峰;;63例重癥膿毒血癥的臨床分析[A];“2008災(zāi)害創(chuàng)傷與急救新進(jìn)展”學(xué)術(shù)交流會(huì)學(xué)術(shù)論文集[C];2008年
3 盧中秋;李景榮;盧才教;程俊彥;黃唯佳;周鐵麗;李秉熙;陳雷;;弧菌性膿毒血癥的早期臨床診斷與治療[A];中華醫(yī)學(xué)會(huì)急診醫(yī)學(xué)分會(huì)第十次全國(guó)復(fù)蘇中毒學(xué)術(shù)論文交流會(huì)論文匯編[C];2004年
4 馮思霞;汪楊;李玉香;王峰;;瘤型麻風(fēng)合并膿毒血癥1例[A];第二屆傳染病診治高峰論壇暨2009年浙江省感染病、肝病學(xué)術(shù)年會(huì)論文匯編[C];2009年
5 劉小彭;高新;周祥福;溫星橋;狄金明;蒲小勇;王德娟;司徒杰;;輸尿管急性梗阻伴膿毒血癥的急診處理(附72例報(bào)告)[A];第十七屆全國(guó)泌尿外科學(xué)術(shù)會(huì)議論文匯編[C];2010年
6 蔣麗;;核因子-κB活化在大鼠膿毒血癥胃腸黏膜屏障中的作用[A];中華醫(yī)學(xué)會(huì)急診分會(huì)第五屆全國(guó)危重病學(xué)術(shù)交流會(huì)論文匯編[C];2004年
7 馬中富;翟誠(chéng)順;梁艷冰;詹紅;唐皓;葉海寧;;膿毒血癥大鼠心肌細(xì)胞凋亡及其機(jī)制研究[A];2005年全國(guó)危重病急救醫(yī)學(xué)學(xué)術(shù)會(huì)議學(xué)術(shù)論文集[C];2005年
8 胡靜;陸國(guó)平;陸鑄今;盧亞芳;賀駿;張靈恩;;新生兒膿毒血癥血液凈化的護(hù)理[A];中華醫(yī)學(xué)會(huì)第十四次全國(guó)兒科學(xué)術(shù)會(huì)議論文匯編[C];2006年
9 胡靜;陸國(guó)平;陸鑄今;盧亞芳;賀駿;張靈恩;;新生兒膿毒血癥血液凈化的護(hù)理[A];2006(第三屆)江浙滬兒科學(xué)術(shù)會(huì)議暨浙江省兒科學(xué)術(shù)年會(huì)論文匯編[C];2006年
10 高巨;;中西醫(yī)結(jié)合對(duì)膿毒血癥發(fā)病機(jī)制和治療的進(jìn)展[A];中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)圍手術(shù)期專業(yè)委員會(huì)成立大會(huì)暨第二屆全國(guó)中西醫(yī)結(jié)合圍手術(shù)期醫(yī)學(xué)專題研討會(huì)論文集[C];2007年
相關(guān)重要報(bào)紙文章 前10條
1 本報(bào)記者 東辰;禮來(lái)膿毒血癥新藥獲準(zhǔn)歐洲上市[N];中國(guó)高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2002年
2 力信 小濤;生物工程點(diǎn)石成金 人體蛋白也成良藥[N];醫(yī)藥經(jīng)濟(jì)報(bào);2002年
3 本報(bào)記者 孫晨 中國(guó)金藥網(wǎng)聯(lián)合報(bào)道;“第一”——禮來(lái)追求的競(jìng)爭(zhēng)高標(biāo)[N];中國(guó)高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2002年
4 陶振峰 李曉明;咽源性縱隔膿腫的診治[N];中國(guó)中醫(yī)藥報(bào);2004年
5 楊冉;痔瘡的危害[N];醫(yī)藥經(jīng)濟(jì)報(bào);2003年
6 ;感染性疾病檢測(cè)醞釀革命[N];中國(guó)醫(yī)藥報(bào);2002年
7 駱景銘;秋癤的防治[N];中國(guó)中醫(yī)藥報(bào);2001年
8 北京協(xié)和醫(yī)院老年示范病房 曲璇 朱鳴雷 劉曉紅;生命終點(diǎn),選擇尊嚴(yán)[N];健康報(bào);2011年
9 王曉麗;年輕女性患闌尾炎治療要徹底[N];農(nóng)村醫(yī)藥報(bào)(漢);2009年
10 杜長(zhǎng)明;少女闌尾炎應(yīng)盡早切除[N];大眾衛(wèi)生報(bào);2002年
相關(guān)博士學(xué)位論文 前10條
1 高蓉;Sirt1在膿毒血癥繼發(fā)的急性肺和腎損傷中的保護(hù)作用[D];吉林大學(xué);2014年
2 謝俊然;羥乙基淀粉130/0.4對(duì)膿毒血癥大鼠全身抗炎作用及相關(guān)機(jī)制研究[D];浙江大學(xué);2010年
3 唐e
本文編號(hào):2196904
本文鏈接:http://sikaile.net/yixuelunwen/jjyx/2196904.html